These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16208322)

  • 41. US election 2020: research and health institutions.
    Jaffe S
    Lancet; 2020 Oct; 396(10259):1320-1321. PubMed ID: 34756174
    [No Abstract]   [Full Text] [Related]  

  • 42. Perspectives. ACT UP: playing the inside & the outside.
    Bryant M
    Faulkner Grays Med Health; 1991 Apr; 45(13):suppl 4 p. PubMed ID: 10109725
    [No Abstract]   [Full Text] [Related]  

  • 43. New president, new congress..... new hope for science?
    Wolinetz CD
    Physiologist; 2009 Feb; 52(1):1, 3-5. PubMed ID: 19271423
    [No Abstract]   [Full Text] [Related]  

  • 44. The outer limits of human genetic engineering: a constitutional examination of parents' procreative liberty to genetically enhance their offspring.
    Patterson TS
    Hastings Constit Law Q; 1999; 26(4):913-33. PubMed ID: 14627050
    [No Abstract]   [Full Text] [Related]  

  • 45. Gene patent study drowned as OTA sinks.
    Macilwain C
    Nature; 1995 Aug; 376(6541):541. PubMed ID: 7637791
    [No Abstract]   [Full Text] [Related]  

  • 46. Cancer institute director's exit leaves NIH in the lurch.
    Davis M
    Nature; 2001 Sep; 413(6853):241. PubMed ID: 11564997
    [No Abstract]   [Full Text] [Related]  

  • 47. Federal funding and the regulation of embryonic stem cell research: the Pontius Pilate maneuver.
    Levine RJ
    Yale J Health Policy Law Ethics; 2009; 9 Suppl():552-64. PubMed ID: 19757720
    [No Abstract]   [Full Text] [Related]  

  • 48. Stem cells by any other name.
    Baker M
    Nature; 2007 Sep; 449(7161):389. PubMed ID: 17898732
    [No Abstract]   [Full Text] [Related]  

  • 49. Federal funding of human embryonic stem cell research: an institutional examination.
    Fujikawa R
    South Calif Law Rev; 2005 May; 78(4):1075-124. PubMed ID: 17340756
    [No Abstract]   [Full Text] [Related]  

  • 50. Head to head: Bush vs Kerry.
    Macilwain C; Bush GW; Kerry J
    Nature; 2004 Sep; 431(7006):238-43. PubMed ID: 15372001
    [No Abstract]   [Full Text] [Related]  

  • 51. Public roundtable on future directions in Women's Health Research at the National Institutes of Health.
    Stone J; Pinn VW; Lawrence M; Lawrence M; Lynch BS
    J Womens Health (Larchmt); 2006 Apr; 15(3):248-50. PubMed ID: 16620183
    [No Abstract]   [Full Text] [Related]  

  • 52. U.S. science policy. Report accuses Bush Administration, again, of 'politicizing' science.
    Lawler A; Kaiser J
    Science; 2004 Jul; 305(5682):323-5. PubMed ID: 15256648
    [No Abstract]   [Full Text] [Related]  

  • 53. U.S. science policy. Cancer institute director tapped for FDA.
    Kaiser J; Couzin J
    Science; 2006 Mar; 311(5768):1692. PubMed ID: 16556808
    [No Abstract]   [Full Text] [Related]  

  • 54. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 55. U.S. biomedical policy. Acting FDA head drops NCI post.
    Kaiser J
    Science; 2005 Oct; 310(5745):29. PubMed ID: 16210502
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of the first 10 years of the Office of Research on Women's Health at the National Institutes of Health: selected findings.
    Stone J; Pinn VW; Rudick J; Lawrence M; Carlyn M
    J Womens Health (Larchmt); 2006 Apr; 15(3):234-47. PubMed ID: 16620182
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA gets Kessler; NIH gets left out.
    Culliton BJ
    Science; 1990 Nov; 250(4982):749. PubMed ID: 2237422
    [No Abstract]   [Full Text] [Related]  

  • 58. Advancing Alzheimer's disease drug review as a national priority.
    Perry DP
    Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reagan is leaving his mark on the Food and Drug Administration.
    Kosterlitz J
    Natl J (Wash); 1985 Jul; 17(27):1568-72. PubMed ID: 10271744
    [No Abstract]   [Full Text] [Related]  

  • 60. The effect of the current regulatory environment on clinical research: An overview.
    Finlayson SR
    Surgery; 2009 Jun; 145(6):626-30. PubMed ID: 19486763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.